Castration resistent metastatic prostate cancer MedDRA version: 14.1 Level: HLT Classification code 10036908 Term: Prostatic neoplasms malignant System Organ Class: 100000004864
Conditions
Interventions
Product Name: mRNA transfected dendritic cell vaccine
Pharmaceutical Form: Injection
Trade Name: Taxotere
Pharmaceutical Form: Concentrate and solvent for solution for infusion
Sponsors
Center for Cancer Immunotherapy (CCIT) / Department of Oncology, Herlev Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: ;Secondary Objective: ;Primary end point(s): ;Timepoint(s) of evaluation of this end point: End of trial | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): At beskrive objektivt respons ved hjælp af WHO’s Response Evaluation Criteria in Solid Tumors (RECIST-kriterier). At evaluere PSA respons At evaluere smerterespons At belyse, hvorvidt kombinationsbehandlingen er en tolerabel og sikker behandling At beskrive tid til progression samt registrere overlevelsen. ;Timepoint(s) of evaluation of this end point: End of trial | — |
Countries
Denmark
Outcome results
None listed